Glucagon-Like Peptide-1: the incretin hormone targeted by semaglutide, tirzepatide, and related weight-loss drugs. Three Cochrane reviews in late 2025 confirmed efficacy. FDA approved the semaglutide pill in December 2025. Stanford researchers identified genetic variants affecting ~10% of the population's response rate in 2026
